AI-assisted, human-published
10/22/2024 /Funding Events
AvenCell Secures $112M to Advance Universal CAR-T Cell Therapy Platform
AvenCell Therapeutics raises $112 million in Series B funding led by Novo Holdings to accelerate the clinical validation of its Universal Switchable CAR-T cell therapy platform, addressing unmet medical needs in hematologic malignancies like Acute Myeloid Leukemia.
AI-assisted, human-published
Latest headlines
-
-
-
Stay connected!
If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here
©2023 VentureCapital.com